For CY 2026, we believed this procedure was still appropriately assigned to APC 5302 (Level 2 Upper GI Procedures), which had a proposed payment rate of $1,975.59
The absence of human RCT data means BPC-157 is genuinely in the research phase not just regulatory-incomplete, but scientifically incomplete for establishing efficacy in humans
Not every patient needs every therapy the plan is tailored to what your body actually needs
Huff T, Mller CS, Otto AM, Netzker R, Hannappel E
QD community oral or SC MOTS-c Daily SC, often 5 days on / 2 off AOD-9604 Daily SC Attribute Max studied dose SLU-PP-332 50 mg/kg BID (mouse, 28 days) MOTS-c 5-15 mg/kg (mouse) AOD-9604 1-5 mg/day in human Phase 2 Attribute Peak efficacy signal SLU-PP-332 ~25-30% fat-mass reduction in DIO mice over 28 days MOTS-c Improved insulin sensitivity in aged mice AOD-9604 Modest fat-loss signal in human Phase 2